Analyst spots strong figures behind Genmab upgrade
Having seen Darzalex revenues boosted by a strong US dollar, the Danish biotech company has raised its 2022 ambitions. But the upgrade is driven by more than just currency effects, an analyst points out.
by marketwire, translated by daniel pedersen
Genmab’s revised financial expectations point to strong underlying growth, assesses Søren Løntoft Hansen, analyst at Danish bank Sydbank.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Genmab upgrades guidance
For subscribers
